Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2013
  • Online publication date: May 2013

15 - Depression in the context of pregnancy

from Section 2 - Medical management

Summary

Multiple studies have demonstrated that psychotic major depression (MDpsy) occurs more frequently in bipolar than in unipolar depression. Most MDpsy patients receive acute treatment on inpatient services. Management begins with establishing the diagnosis. DSM-IV recognizes that depression may occur during the prodromal, active, and residual phases of schizophrenia, and limits MDpsy to patients whose episodes of psychosis occur exclusively during episodes of major depressive disorder (MDD). An appropriate goal of acute treatment is to achieve both the remission of major depression and the resolution of delusional ideas. Remarkably little systematic data is available to guide continuation treatment to prevent relapses in the 4-6 months following remission and no studies are available on the prevention of recurrences after 6 months. The outcomes of untreated or inadequately treated MDpsy are poor, with high rates of suicide attempts, recurrences, and residual disability.

References

Alwan, S., Reefhuis, J., Rasmussen, S.A.et al. (2007). Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. New England Journal of Medicine, 356, 2684–2692.
Alwan, S., Reefhuis, J., Botto, L.D.et al. (2010). National Birth Defects Prevention Study: Maternal use of bupropion and risk for congenital heart defects. American Journal of Obstetrics and Gynecology, 203, 52.e1–52.e6.
Alwan, S., Reefhuis, J., Rasmussen, S.A.et al. (2011). National Birth Defects Prevention Study: Patterns of antidepressant medication use among pregnant women in a United States population. J Clin Pharmacology, 51, 264–270.
Anderson, E.L. and Reti, I.M. (2009). ECT in pregnancy: a review of the literature from 1941 to 2007. Psychosomatic Medicine, 71, 235–242.
Beck, C.T. (1996). A meta-analysis of predictors of postpartum depression. Nurse Researcher, 45, 297–303.
Bennett, H.A., Einarson, A., Taddio, A.et al. (2004). Depression during pregnancy: Overview of clinical factors. Clinical Drug Investigation, 24, 157–179.
Berle, J.O. and Spigset, O. (2011). Antidepressant use during breastfeeding. Current Women's Health Reviews, 7, 28–34.
BroyP. and BérardA. (2010). Gestational exposure to antidepressants and the risk of spontaneous abortion: A review. Current Drug Delivery, 7, 76–92.
Casper, R.C., Fleisher, B.E., Lee-Ancajas, J.C.et al. (2003). Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. Journal of Pediatrics, 142, 402–408.
CDC (2008). Centers for Disease Control and Prevention: update on overall prevalence of major birth defects: Atlanta, Georgia, 1978–2005. Morbidity and Mortality Weekly Report, 57,1–5.
Chambers, C. (2009). Selective serotonin reuptake inhibitors and congenital malformations. British Medical Journal, 33, 703–704.
Chambers, C.D., Johnson, K.A., Dick, L.M.et al. (1996). Birth outcomes in pregnant women taking fluoxetine. New England Journal of Medicine, 335, 1010–1015.
Chun-Fai-Chan, B., Koren, G., Fayez, I.et al. (2005). Pregnancy outcome of women exposed to bupropion during pregnancy: A prospective comparative study. American Journal of Obstetrics and Gynecology, 192, 932–936.
Cole, J.A., Ephross, S.A., Cosmatos, I.S.et al. (2007). Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiology and Drug Safety, 16, 1075–1085.
Croen, L.A., Grether, J.K., Yoshida, C.K.et al. (2011). Antidepressant use during pregnancy and childhood autism spectrum disorders. Archives of General Psychiatry, 68, 1104–1112.
Daniels, J.L., Forssen, U., Hultman, C.M.et al. (2008). Parental psychiatric disorders associated with autism spectrum disorders in the offspring. Pediatrics, 121, 1357–1362.
Davis, R.L., Rubanowise, D., McPhillips, H.et al. (2007). Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiology and Drug Safety, 16, 1086–1094.
Deave, T., Heron, J., Evans, J.et al. (2008). The impact of maternal depression in pregnancy on early child development. International Journal of Obstetrics and Gynaecology, 115, 1043–1051.
Dennis, C.L. and Hodnett, E. (2007). Psychosocial and psychological interventions for treating postpartum depression. Cochrane Database of Systematic Reviews, 17, CD006116.
Djulus, J., Koren, G., Einarson, A.et al. (2006). Exposure to Mirtazapine during pregnancy: A prospective, comparative study of birth outcomes. Journal of Clinical Psychiatry, 67, 1280–1284.
Eberhard-Gran, M., Eskild, A., and Opjordsmoen, S. (2005). Treating mood disorders during pregnancy: Safety considerations. Drug Safety, 28, 695–706.
Einarson, A. and Boskovic, R. (2009). Use and safety of antipsychotic drugs during pregnancy. Journal of Psychiatric Practice, 15, 183–192.
Einarson, A., Fatoye, B., Sarkar, M. et al. (2001). Pregnancy outcome following gestational exposure to venlafaxine: A multicenter prospective controlled study. American Journal of Psychiatry, 158, 1728–1730.
Einarson, A., Bonari, L., Voger-Lavigne, S.et al. (2003). A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Canadian Journal of Psychiatry, 48, 106–110.
Einarson, A., Choi, J., Einarson, T.R.et al. (2009). Incidence of major malformations in infants following antidepressant exposure in pregnancy: Results of a large prospective cohort study. Canadian Journal of Psychiatry, 54, 242–246.
Einarson, T.R. and Einarson, A. (2005). Newer antidepressants in pregnancy and rates of major malformations: A meta-analysis of prospective comparative studies. Pharmacoepidemiology and Drug Safety, 14, 823–827.
Figueroa, R. (2010). Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring. Journal of Devopmental and Behavioral Pediatrics, 31, 641–648.
Gavin, N.I., Gaynes, B.N., Lohr, K.N.et al. (2005). Perinatal depression: a systematic review of prevalence and incidence. Obstetrics and Gynecology, 106, 1071–1083.
Gaynes, B.N., Gavin, N., Meltzer-Brody, S.et al. (2005). Perinatal Depression: Prevalence, Screening Accuracy, and Screening Outcomes. Evidence Report/Technology Assessment No. 119. AHRQ Publication No. 05-E006–1. Agency for Healthcare Research and Quality. US Department of Health and Human Services.
GlaxoSmithKlein (2006). Updated preliminary report on bupropion and other antidepressants including paroxetine in pregnancy, and the occurrence of cardiovascular and other major malformations.
Grote, N.K., Bridge, J.A., Gavin, A.R.et al. (2010). A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Archives of General Psychiatry, 67, 1012–1024.
Heinonen, O.P., Slone, D., and Shapiro, S. (1999). Birth Defects and Drugs in Pregnancy. Littleton, MA: Publishing Sciences Group.
Horrigan, T.J., Schroeder, A.V., and Schaffer, R.M. (2000). The triad of substance abuse, violence, and depression are interrelated in pregnancy. Journal of Substance Abuse, 18, 55–58.
Husain, M.M., Stegman, D., and Trevino, K. (2005). Pregnancy and delivery while receiving vagus nerve stimulation for the treatment of major depression: a case report. Annals of General Psychiatry, 4, 16.
Jones, I.N. and Craddock, N. (2001). Familiality of the puerperal trigger in bipolar disorder: Results of a family study. American Journal of Psychiatry, 158, 913–917.
Källén, B.A. and Otterblad Olausson, P. (2003). Maternal drug use in early pregnancy and infant cardiovascular defect. Reproductive Toxicology, 17, 255–261.
KällénB.A. and Otterblad Olausson, P. (2007). Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Research A, Clinical and Molecular Teratology, 79, 301–308.
Kelly, R.H., Danielsen, B., Golding, J.et al. (1999). Adequacy of prenatal care among women with psychiatric diagnoses giving birth in California in 1994 and 1995. Psychiatric Services, 50, 1584–1590.
Kieler, H., Artama, M., Engeland, A.et al. (2012). Selective serotonin reuptake inhibitors and risk of persistent pulmonary hypertension in the newborn: Population based cohort study from the five Nordic countries. British Medical Journal, 344, d8012.
Kim, D.R., Epperson, N., Paré, E.et al. (2011). An open label pilot study of transcranial magnetic stimulation for pregnant women with major depressive disorder. Journal of Women's Health, 20, 255–261.
Kulin, N.A., Pastuszak, A., Sage, S.A.et al. (1998). Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: A prospective controlled multicenter study. Journal of the American Medical Association, 279, 609–610.
Kupfer, D.J. and Frank, E. (1987). Relapse in recurrent unipolar depression. American Journal of Psychiatry, 144, 86–88.
Kurki, T., Hiilesmaa, V., Raitasalo, R.et al. (2000). Depression and anxiety in early pregnancy and risk for preeclampsia. Obstetrics and Gynecology, 95, 487–490.
Laine, K., Heikkinen, T., Ekblad, U., and Kero, P. (2003). Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Archives of General Psychiatry, 60, 720–726.
Lennestal, R. and Källén, B. (2007). Delivery outcome in relation to maternal use of some recently introduced antidepressants. Journal of Clinical Psychopharmacology, 27, 607–613.
Levinson-Castiel, R., Merlob, P., Linder, N.et al. (2006). Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Archives of Pediatric and Adolescent Medicine, 160, 173–176.
Logsdon, M.C., Davis, D.W., Birkimer, J.C.et al. (1997). Predictors of depression in mothers of pre-term infants. Journal of Social Behavior and Personality, 12, 73–88.
Lorenzo, L., Byers, B., and Einarson, A. (2011). Antidepressant use in pregnancy. Expert Opinion on Drug Safety, 10, 883–889.
Louik, C., Lin, A.E., Werler, M.M.et al. (2007). First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. New England Journal of Medicine, 356, 2675–2683.
Malm, H., Klaukka, T., and Neuvonen, P.J. (2005). Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstetrics and Gynecology, 106, 1289–1296.
Malm, H., Artama, M., Gissler. M.et al. (2011). Serotonin reuptake inhibitors and risk for major congenital anomalies. Obstetrics and Gynecology, 118, 111–120.
Manber, R., Schnyer, R.N., Lyell, D.et al. (2010). Acupuncture for depression during pregnancy: A randomized controlled trial. Obstetrics and Gynecology, 115, 511–520.
McElhatton, P.R., Garbis, H.M., Eléfant, E. et al. (1996). The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants: A collaborative study of the European Network of Teratology Information Services (ENTIS). Reproductive Toxicology, 10, 285–294.
Misri, S., Reebye, P., Kendrick, K.et al. (2006). Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. American Journal of Psychiatry, 163, 1026–1032.
Moses-Kolko, E.L., Bogen, D., Perel, J.et al. (2005). Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: Literature review and implications for clinical applications. Journal of the American Medical Association, 293, 2372–2383.
Munk-Olsen, T., Laursen, T.M., Pedersen, C.B.et al. (2006). New parents and mental disorders: A population-based register study. Journal of American Medical Association, 296, 2582–2589.
Murray, L., Cooper, P., and Hipwell, A. (2003). Mental health of parents caring for infants. Archives of Women's Mental Health, 6 Suppl 2, S71–S77.
Ng, R.C., Hirata, C.K., Yeung, W.et al. (2010). Pharmacologic treatment for postpartum depression: a systematic review. Pharmacotherapy, 30(9), 928–41.
Nulman, I., Rovet, J., Stewart, D.E.et al. (2002). Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. American Journal of Psychiatry, 159, 1889–1895.
Oberlander, T.F., Warburton, W., Misri, S.et al. (2006). Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor anti-depressants and maternal depression using population-based linked health data. Archives of General Psychiatry, 63, 898–906.
Oberlander, T.F., Warburton, W., Misri, S.et al. (2008). Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. British Journal of Psychiatry, 92, 338–343.
Occhiogrosso, M., Omran, S.S., and Altemus, M. (2012). Persistent pulmonary hypertension of the newborn and SSRIs: Lessons from clinical and translational studies. American Journal of Psychiatry, 169, 134–140.
O’Connor, T.G., Heron, J., Golding, J.et al. (2002). Maternal antenatal anxiety and children's behavioural/emotional problems at 4 years. British Journal of Psychiatry, 80, 502–508.
Pedersen, L.H., Henriksen, T.B., and Vestergaard, M. (2009). Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: Population based cohort study. British Medical Journal, 339, b3569.
Pedersen, L.H., Henriksen, T.B., and OlsenJ. (2010). Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics, 125, 600–608.
Petersen, I., Gilbert, R.E., and Evans, S.J. (2011). Pregnancy as a major determinant for discontinuation of antidepressants: An analysis of data from The Health Improvement Network. Clinical Psychiatry, 72, 979–985.
Reimers, A., Helde, G., Bråthen, G., et al. (2011). Lamotrigine and its N2-glucuronide during pregnancy: the significance of renal clearance and estradiol. Epilepsy Research, Feb 26, epub ahead of print.
Reis, M. and Källén, B. (2010). Delivery outcome after maternal use of antidepressant drugs in pregnancy: An update using Swedish data. Psychological Medicine, 40, 1723–1733.
Shamsi, U., Hatcher, J., Shamsi, A.et al. (2010). A multicentre matched case control study of risk factors for preeclampsia in healthy women in Pakistan. BMC Women's Health, 10, 14.
Sit, D.K., Perel, J.M., Helsel, J.C.et al. (2008). Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. Journal of Clinical Psychiatry, 69, 652–658.
Spinelli, M.G. (1997). Interpersonal psychotherapy for depressed antepartum women: A pilot study. American Journal of Psychiatry, 154, 1028–1030.
Spinelli, M.G. (2012). Antidepressant treatment during pregnancy. American Journal of Psychiatry, 169, 121–124.
Spinelli, M.G. and Endicott, J. (2003). Controlled clinical trial of interpersonal psychotherapy versus parenting education program for depressed pregnant women. American Journal of Psychiatry, 160, 555–562.
Su, K.P., Huang, S.Y., Chiu, T.H.et al. (2008). Omega-3 fatty acids for major depressive disorder during pregnancy: Results from a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry, 69, 633–634.
Troutman, B. and Cutrona, C. (1990). Nonpsychotic postpartum depression among adolescents. Journal of Abnormal Psychology, 99, 69–78.
Udechuku, A., Nguyen, T., Hill, R.et al. (2010). Antidepressants in pregnancy: A systematic review. Australian and New Zealand Journal of Psychiatry, 44, 978–996.
Viguera, A.C., Whitfield, T., Baldessarini, R.J.et al. (2007). Risk of recurrence in women with bipolar disorder during pregnancy: Prospective study of mood stabilizer discontinuation. American Journal of Psychiatry, 164, 1817–1824.
Warburton, W., Hertzman, C., and Oberlander, T.F. (2010). A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatrica Scandanavica, 121, 471–479.
Wichman, C.L., Moore, K.M., Lang, T.R.et al. (2009). Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clinic Proceedings, 84, 23–27.
Wirz-Justice, A., Bader, A., Frisch, U.et al. (2011). A randomized, double-blind, placebo-controlled study of light therapy for antepartum depression. Journal of Clinical Psychiatry, 72, 986–993.
Wisner, K.L., Zarin, D.A., Holmboe, E.S.et al. (2000). Risk-benefit decision making for treatment of depression during pregnancy. American Journal of Psychiatry, 157, 1933–1940.
Wisner, K.L., Sit, D.K., Hanusa, B.H.et al. (2009). Major depression and antidepressant treatment: Impact on pregnancy and neonatal outcomes. American Journal of Psychiatry, 166, 557–566.
Wurst, K.E., Poole, C., Ephross, S.A.et al. (2010). First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: A meta-analysis of epidemiological studies. Birth Defects Research A, Clinical and Molecular Teratology, 88, 159–170.
Yonkers, K.A., Wisner, K.L., Stowe, Z.et al. (2004). Management of bipolar disorder during pregnancy and the postpartum period. American Journal of Psychiatry, 161, 608–620.
Yonkers, K.A., Wisner, K.L., Stewart, D.E.et al. (2009). The management of depression during pregnancy: A report from the American Psychiatry Association and the American College of Obstetricians and Gynecologists. Obstetrics and Gynecology, 114, 703–713.